HMGB1 suppression confers neuroprotection against stroke in diabetic rats

[1] Ergul A., Li W., Elgebaly M.M., Bruno A., Fagan S.C., Hyperglycemia, diabetes and stroke: focus on the cerebrovasculature, Vascul. Pharmacol., 2009, 51, 44–49 http://dx.doi.org/10.1016/j.vph.2009.02.00410.1016/j.vph.2009.02.004Search in Google Scholar

[2] Luitse M.J., Biessels G.J., Rutten G.E., Kappelle L.J., Diabetes, hyperglycaemia, and acute ischaemic stroke, Lancet Neurol., 2012, 11, 261–271 http://dx.doi.org/10.1016/S1474-4422(12)70005-410.1016/S1474-4422(12)70005-4Search in Google Scholar

[3] Uyttenboogaart M., Koch M.W., Stewart R.E., Broomen P.C., Luijckx G.J., De Keyser J., Moderate hyperglycaemia is associated with favourable outcome in acute lacunar stroke, Brain, 2007, 130, 1626–1630 http://dx.doi.org/10.1093/brain/awm08710.1093/brain/awm087Search in Google Scholar

[4] Capes S.E., Hunt D., Malmberg K., Pathak P., Gerstein H.C., Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview, Stroke, 2001, 32, 2426–2432 http://dx.doi.org/10.1161/hs1001.09619410.1161/hs1001.096194Search in Google Scholar

[5] MacDougall N.J., Muir K.W., Hyperglycaemia and infarct size in animal models of middle cerebral artery occlusion: systematic review and meta-analysis, J. Cereb. Blood Flow Metab., 2011, 31, 807–818 http://dx.doi.org/10.1038/jcbfm.2010.21010.1038/jcbfm.2010.210Search in Google Scholar

[6] Quast M.J., Wei J., Huang N.C., Brunder D.G., Sell S.L., Gonzales J.M., et al., Perfusion deficit parallels exacerbation of cerebral ischemia/reperfusion injury in hyperglycemic rats, J. Cereb. Blood Flow Metab., 1997, 17, 553–559 http://dx.doi.org/10.1097/00004647-199705000-0000910.1097/00004647-199705000-00009Search in Google Scholar

[7] Kawai N., Keep R.F., Betz A.L., Nagao S., Hyperglycemia induces progressive changes in the cerebral microvasculature and bloodbrain barrier transport during focal cerebral ischemia, Acta Neurochir. Suppl., 1998, 71, 219–221 10.1007/978-3-7091-6475-4_63Search in Google Scholar

[8] Nogueira-Machado J.A., Volpe C.M., Veloso C.A., Chaves M.M., HMGB1, TLR and RAGE: a functional tripod that leads to diabetic inflammation, Expert Opin. Ther. Targets, 2011, 15, 1023–1035 http://dx.doi.org/10.1517/14728222.2011.57536010.1517/14728222.2011.575360Search in Google Scholar

[9] Wang H., Bloom O., Zhang M., Vishnubhakat J.M., Ombrellino M., Che J., et al., HMG-1 as a late mediator of endotoxin lethality in mice, Science, 1999, 285, 248–251 http://dx.doi.org/10.1126/science.285.5425.24810.1126/science.285.5425.248Search in Google Scholar

[10] Urbonaviciute V., Fürnrohr B.G., Meister S., Munoz L., Heyder P., De Marchis F., et al., Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: Implications for the pathogenesis of SLE, J. Exp. Med., 2008, 205, 3007–3018 http://dx.doi.org/10.1084/jem.2008116510.1084/jem.20081165Search in Google Scholar

[11] Arase Y., Ikeda K., Murashima N., Chayama K., Tsubota A., Koida I., et al., The long term efficacy of glycyrrhizin in chronic hepatitis c patients, Cancer, 1997, 79, 1494–1500 http://dx.doi.org/10.1002/(SICI)1097-0142(19970415)79:8<1494::AID-CNCR8>3.0.CO;2-B10.1002/(SICI)1097-0142(19970415)79:8<1494::AID-CNCR8>3.0.CO;2-BSearch in Google Scholar

[12] Mollica L., De Marchis F., Spitaleri A., Dallacosta C., Pennacchini D., Zamai M., et al., Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities, Chem. Biol., 2007, 14, 431–441 http://dx.doi.org/10.1016/j.chembiol.2007.03.00710.1016/j.chembiol.2007.03.007Search in Google Scholar

[13] Kim C.K., Kim T., Choi I.Y., Soh M., Kim D., Kim Y.J., et al., Ceria nanoparticles that can protect against ischemic stroke, Angew. Chem. Int. Ed. Engl., 2012, 51, 11039–11043 http://dx.doi.org/10.1002/anie.20120378010.1002/anie.201203780Search in Google Scholar

[14] Wang Q., Tang X.N., Yenari M.A., The inflammatory response in stroke, J. Neuroimmunol., 2007, 184, 53–68 http://dx.doi.org/10.1016/j.jneuroim.2006.11.01410.1016/j.jneuroim.2006.11.014Search in Google Scholar

[15] Goldstein R.S., Gallowitsch-Puerta M., Yang L., Rosas-Ballina M., Huston J.M., Czura C.J., et al., Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia, Shock, 2006, 25, 571–574 http://dx.doi.org/10.1097/01.shk.0000209540.99176.7210.1097/01.shk.0000209540.99176.72Search in Google Scholar

[16] Huang J.M., Hu J., Chen N., Hu M.L., Relationship between plasma high-mobility group box-1 levels and clinical outcomes of ischemic stroke, J. Crit. Care, 2013, 28, 792–797 http://dx.doi.org/10.1016/j.jcrc.2012.10.00310.1016/j.jcrc.2012.10.003Search in Google Scholar

[17] Devaraj S., Dasu M.R., Park S.H., Jialal I., Increased levels of ligands of Toll-like receptors 2 and 4 in type 1 diabetes, Diabetologia, 2009, 52, 1665–1668 http://dx.doi.org/10.1007/s00125-009-1394-810.1007/s00125-009-1394-8Search in Google Scholar

[18] Goldin A., Beckman J.A., Schmidt A.M., Creager M.A., Advanced glycation end products: sparking the development of diabetic vascular injury, Circulation, 2006, 114, 597–605 http://dx.doi.org/10.1161/CIRCULATIONAHA.106.62185410.1161/CIRCULATIONAHA.106.621854Search in Google Scholar

[19] Tsuruta R., Fujita M., Ono T., Koda Y., Yamamoto T., Nanba M., et al., Hyperglycemia enhances excessive superoxide anion radical generation, oxidative stress, early inflammation, and endothelial injury in forebrain ischemia/reperfusion rats, Brain Res., 2010, 1309, 155–163 http://dx.doi.org/10.1016/j.brainres.2009.10.06510.1016/j.brainres.2009.10.065Search in Google Scholar

[20] Dasu M.R., Devaraj S., Park S., Jialal I., Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects, Diabetes Care, 2010, 33, 861–868 http://dx.doi.org/10.2337/dc09-179910.2337/dc09-1799Search in Google Scholar

[21] Yang Q.W., Lu F.L., Zhou Y., Wang L., Zhong Q., Lin S., et al., HMBG1 mediates ischemia-reperfusion injury by TRIF-adaptor independent Toll-like receptor 4 signaling, J. Cereb. Blood Flow Metab., 2011, 31, 593–605 http://dx.doi.org/10.1038/jcbfm.2010.12910.1038/jcbfm.2010.129Search in Google Scholar

[22] Andersson U., Tracey K.J., HMGB1 is a therapeutic target for sterile inflammation and infection, Annu. Rev. Immunol., 2011, 29, 139–162 http://dx.doi.org/10.1146/annurev-immunol-030409-10132310.1146/annurev-immunol-030409-101323Search in Google Scholar

[23] Hofmann M.A., Drury S., Fu C., Qu W., Taguchi A., Lu Y., et al., RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides, Cell, 1999, 97, 889–901 http://dx.doi.org/10.1016/S0092-8674(00)80801-610.1016/S0092-8674(00)80801-6Search in Google Scholar

[24] Ishihara K., Tsutsumi K., Kawane S., Nakajima M., Kasaoka T., The receptor for advanced glycation end-products (RAGE) directly binds to ERK by a D-domain-like docking site, FEBS Lett., 2003, 550, 107–113 http://dx.doi.org/10.1016/S0014-5793(03)00846-910.1016/S0014-5793(03)00846-9Search in Google Scholar

[25] Touré F., Zahm J.M., Garnotel R., Lambert E., Bonnet N., Schmidt A.M., et al., Receptor for advanced glycation end-products (RAGE) modulates neutrophil adhesion and migration on glycoxidated extracellular matrix, Biochem. J., 2008, 416, 255–261 http://dx.doi.org/10.1042/BJ2008005410.1042/BJ20080054Search in Google Scholar

[26] Li J., Schmidt A.M., Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products, J. Biol. Chem., 1997, 272, 16498–16506 http://dx.doi.org/10.1074/jbc.272.26.1649810.1074/jbc.272.26.16498Search in Google Scholar

[27] Kim J.B., Sig Choi J., Yu Y.M., Nam K., Piao C.S., Kim S.W., et al., HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain, J. Neurosci., 2006, 26, 6413–6421 http://dx.doi.org/10.1523/JNEUROSCI.3815-05.200610.1523/JNEUROSCI.3815-05.2006Search in Google Scholar

[28] Muhammad S., Barakat W., Stoyanov S., Murikinati S., Yang H., Tracey K.J., et al., The HMGB1 receptor RAGE mediates ischemic brain damage, J. Neurosci., 2008, 28, 12023–12031 http://dx.doi.org/10.1523/JNEUROSCI.2435-08.200810.1523/JNEUROSCI.2435-08.2008Search in Google Scholar

[29] Takii H., Kometani T., Nishimura T., Nakae T., Okada S., Fushiki T., Antidiabetic effect of glycyrrhizin in genetically diabetic KK-Ay mice, Biol. Pharm. Bull., 2001, 24, 484–487 http://dx.doi.org/10.1248/bpb.24.48410.1248/bpb.24.484Search in Google Scholar

[30] Sen S., Roy M., Chakraborti A.S., Ameliorative effects of glycyrrhizin on streptozotocin-induced diabetes in rats, J. Pharm. Pharmacol., 2011, 63, 287–296 http://dx.doi.org/10.1111/j.2042-7158.2010.01217.x10.1111/j.2042-7158.2010.01217.xSearch in Google Scholar